CEO
RNhale
Munich, Bayern, Germany
Benjamin Winkeljann is an engineer with a extensive experience in nanoparticle development for nucleic acid delivery. He is a group leader within the Institute for Pharmaceutical Technology at LMU Munich and CEO of the spin-off company RNhale which develops inhalable RNA formulations for the treatment of respiratory diseases. Dr. Winkeljann has a passion for translating research into market applications, a strong track record in research management, funding acquisition, and stakeholder relations. Throughout his career, Dr. Winkeljann has spearheaded interdisciplinary research projects, secured funding from various sources, and published numerous scientific articles.
Monday, July 24, 2023
5:00 PM – 7:00 PM US PST
